

# Puma Biotechnology

## Earnings Call

### Commercial Update



March 3, 2022

**nerlynx**<sup>®</sup>  
(neratinib) tablets




## Forward-Looking Safe-Harbor Statement


*This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2021. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.*



# PUMA's Pharmacy and Distributor Network




# ~\$51 Million net NERLYNX revenue in Q4'21




# 3,454 Ex-factory bottles were sold in Q4'21

Bottles Sold (SP + SD) by Quarter



Includes Commercial SP and SD







# ~60% of patients in Q4'21 started at a reduced dose\* \*\*



\*Reduced dose defined as fewer than 6 pills per day

\*\* FDA approved dose-escalation label supplement in June 2021

# Rest of World Partnerships – Timelines

| Region  | Partner   | Regulatory Approvals  | Commercial Launches   |
|---|---|---|---|
| Australia / SE Asia   |  Specialised Therapeutics                | <ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. in Australia, Singapore</li> <li>• 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand</li> </ul>   | <ul style="list-style-type: none"> <li>• 2020 – Singapore</li> <li>• Q2 2021 – Malaysia</li> <li>• Q3 / Q4 2021 – Brunei, New Zealand</li> </ul>  |
| Israel  |  MEDISON<br>Driving innovative medicines | <ul style="list-style-type: none"> <li>• 2020 – Approved in Ext. Adj. and mBC</li> </ul>  | <ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>   |
| Canada  |  Knight                                  | <ul style="list-style-type: none"> <li>• 2019 – Ext.. Adj. approved</li> <li>• Q2 2021 – mBC approved</li> </ul>  | <ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>   |
| Latin America   |  PINT PHARMA                             | <ul style="list-style-type: none"> <li>• 2019 – Ext Adj in Argentina</li> <li>• 2020 – Ext. Adj in Chile, Ecuador</li> <li>• 2020 – mBC in Argentina</li> <li>• 2021 – Ext Adj and mBC in Peru; mBC in Chile</li> <li>• Q4 2021 – Ext. Adj. in Brazil</li> <li>• Q1 2022 – Ext. Adj. in Mexico</li> </ul> | <ul style="list-style-type: none"> <li>• 2020 – Argentina</li> <li>• Q2 2021 – Chile</li> <li>• Q4 2021 – Peru</li> </ul>   |
| Europe<br>Greater China<br>Middle East<br>North and West Africa<br>South Africa<br>Turkey |  Pierre Fabre                          | <ul style="list-style-type: none"> <li>• 2019 – EMA approval</li> <li>• 2019 – Ext. Adj. in Hong Kong</li> <li>• 2020 – Ext. Adj. in China, Taiwan</li> <li>• Q4 2021 – mBC in Taiwan</li> </ul>  | <ul style="list-style-type: none"> <li>• 2019 – Germany, UK, Austria</li> <li>• 2020 – Sweden, Finland, Scotland, Switzerland, Denmark</li> <li>• 2020 – Hong Kong</li> <li>• Q1 2021 – China (added to 2021 NRDL), Taiwan</li> <li>• Q1 2021 – Greece, Czech Republic</li> </ul> |
| South Korea   |  BIXINK<br>THERAPEUTICS                | <ul style="list-style-type: none"> <li>• Q4 2021 – Ext. Adj. in S. Korea</li> </ul>   | <ul style="list-style-type: none"> <li>• Q1 2022 – Launched</li> </ul>  |

# Puma Biotechnology

## Earnings Call

### Commercial Update



March 3, 2022

**nerlynx**<sup>®</sup>  
(neratinib) tablets

